Abstract
In this Perspective linked to Koenig and colleagues, Elvin Geng and Diane Havlir discuss the next challenges for implementation research around rapid start antiretroviral treatment.
Highlights
Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California, United States of America a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
In an individual randomized trial, Rosen and colleagues found rapid antiretroviral therapy (ART) initiation in South Africa led to a higher proportion of patients initiating ART within 90 days and suppressed at 10 months (51% versus 64%, risk difference: 13%; 95% CI 3% to 23%)
Optimizing how to approach treatment in a way that enables same-day start is more important than ever given global ambitions to treat all persons living with HIV
Summary
Starting antiretroviral therapy (ART) as soon as possible after HIV infection has clear biological and clinical benefits [1]. Healthcare workers, and patients interact to deliver, prescribe, take up, and adhere to medications. Studies have found that the introduction of technologies and streamlined clinical operations can minimize delays [9], data are lacking on how to shape what the diagnosis, and the prospect of treatment, means to patients, despite the fact that this meaning is likely to drive subsequent engagement, stabilization, and behavior after HIV diagnosis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
